1 Introduction The prevalence of type 2 diabetes mellitus (T2DM) has been on the rise globally in recent years, with data from the International Diabetes Federation (IDF) showing that there will be 783.2 million people (12.2%) living with diabetes by 2045 ( Standards of Care in Diabetes the addition of GLP-1RAs and/or SGLT2 inhibitors (SGLT2i) to the treatment plan for patients with T2DM who have been diagnosed with or are at high risk of atherosclerotic cardiovascular disease (ASCVD) ( However, the occurrence of gastrointestinal side effects (GISEs) has challenged the application of GLP-1RAs, which were clinically characterized by symptoms such as nausea (42.23%), vomiting (21.90%), diarrhea (21.93%), and constipation (8.41%) ( 2 Methods 2.1 Research design 2.1.1 Study participants and data sources The data used in the study were derived from the healthcare big data platform and the electronic medical record system of the First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
GLP-1 for Weight Loss: Avoid These 5 Common Mistakes By India Hanley June 28, 2024 Ready to ditch the frustration and finally achieve your weight loss goals
Lichens and bryophytes: light stress and photoinhibition in desiccation/rehydration cyclesmechanisms of photoprotection
Availability : Available in SA as of February 2025
Recommended Dosage : Standard Formula ideal for managing appetite and regulating blood sugar, fitting the regions growing demand for practical, effective weight management solutions
Your provider may adjust your treatment plan accordingly
:max_bytes(150000):strip_icc()/WhatstheDifferenceBetweenOzempicWegovyandMounjaro-illo-a8f5a23fe4914586b4488472fe15f112.png)
